Net Worth Advisory Group Cuts Position in Sanofi (NASDAQ:SNY)

Net Worth Advisory Group trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 4.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,940 shares of the company’s stock after selling 207 shares during the period. Net Worth Advisory Group’s holdings in Sanofi were worth $238,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Synergy Asset Management LLC purchased a new stake in Sanofi during the 4th quarter valued at about $25,000. McClarren Financial Advisors Inc. boosted its stake in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Sunbelt Securities Inc. increased its holdings in shares of Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares in the last quarter. Sierra Ocean LLC bought a new position in shares of Sanofi during the fourth quarter valued at $44,000. Finally, Versant Capital Management Inc purchased a new stake in shares of Sanofi during the fourth quarter valued at $54,000. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on SNY shares. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $60.00.

Sanofi Stock Performance

NASDAQ:SNY opened at $58.74 on Wednesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46. The stock has a 50-day simple moving average of $53.08 and a two-hundred day simple moving average of $52.78. The firm has a market capitalization of $149.07 billion, a PE ratio of 23.59, a P/E/G ratio of 1.01 and a beta of 0.58. Sanofi has a 52-week low of $45.22 and a 52-week high of $60.12.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.